Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Type I interferon (IFN) production is a cellular stress response, but its role in cancer, particularly chronic lymphocytic leukemia (CLL), is complex and not fully understood.
• Cancer cells, including those in CLL, experience stress, yet their IFN response mechanisms and implications remain incompletely elucidated.

Purpose of the Study:

• To investigate the role and significance of autocrine Type I IFN signaling in human chronic lymphocytic leukemia (CLL) cells.
• To determine if CLL cell responses to IFN correlate with clinical behavior and specific genetic markers.

Main Methods:

• Cultured CLL cells were treated with anifrolumab, a neutralizing antibody against the IFN-alpha receptor 1 (IFNAR1).
• IFN pathway activation markers (p-STAT1, p-STAT2, IFN-stimulated genes) and protein expression (IFNAR1, MX1, STAT1, STAT2) were assessed.
• Correlation analysis was performed between IFN response, clinical behavior (unmutated IGHV, CD38, p-BTK expression), and phosphatase activity.

Main Results:

• CLL cells produce low levels of IFN via TANK-binding kinase 1 pathways.
• Anifrolumab blocked IFN signaling in a subset of CLL cells, particularly those with aggressive features (unmutated IGHV, high CD38, p-BTK).
• Hypersensitivity to IFN, linked to higher IFNAR1, MX1, STAT1, STAT2 expression and lower phosphatase activity, protected CLL cells in vitro from stress and drugs (ibrutinib, venetoclax) by upregulating Mcl-1.

Conclusions:

• Hypersensitivity to autocrine Type I IFN signaling in CLL cells is associated with more aggressive clinical behavior.
• Blocking IFN signaling may represent a therapeutic strategy for improving outcomes in high-risk CLL patients.